Toronto, Canada (PRWEB) November 04, 2013
With steadily increasing drug development costs and timelines and the desire to access global patient populations, conducting clinical trials in Asian countries has rapidly become an appealing option for many pharmaceutical companies. However, conducting studies in these countries requires very careful planning to succeed. Accessing global patient populations in emerging markets requires a firm understanding of how to approach differences in culture, language, business practices, and regulatory frameworks. Furthermore, recent trends in population dynamics and diseases and their impact on healthcare have been shaping the future of clinical trials in Asia and particularly in China.
In this webinar, an overview of the market environment along with the key operational, logistical, and regulatory aspects of conducting clinical trials in China and other Asian countries will be discussed by Dr. Patrice Hugo, Chief Scientist for Scientific Affairs at LabCorp Clinical Trials, and Dr. Li Yan, Executive Director of Clinical Development for Infectious Diseases, Oncology, Respiratory & Immunology, and Vaccines in Emerging Markets at Merck.
Copyright©2012 Vocus, Inc.
All rights reserved